

**POSTER PRESENTATION**

**Open Access**

# Enhancing T cell persistence of CAR-redirectioned T cells in solid tumors

Sonia Guedan<sup>1\*</sup>, Shannon E McGettigan<sup>2</sup>, Avery D Posey<sup>1</sup>, Jihyun Lee<sup>3</sup>, Omkar Kawalekar<sup>1</sup>, Prachi R Patel<sup>1</sup>, Brian Keith<sup>1</sup>, Carl June<sup>1</sup>

From Society for Immunotherapy of Cancer 29th Annual Meeting  
National Harbor, MD, USA. 6-9 November 2014

T cell persistence is likely to promote long-term anti-tumor effects after adoptive T cell transfer. We have recently shown that incorporation of the ICOS intracellular domain into chimeric antigen receptors (CARs) significantly increased Th17 cell persistence *in vivo*, compared to CARs with CD28 or 4-1BB intracellular domains [1]. Here, we hypothesized that CD4<sup>+</sup> and CD8<sup>+</sup> T cells require distinct cytokine and costimulation signals for optimal persistence. To test this hypothesis, we compared the *in vivo* antitumor effects and persistence of combined CD4<sup>+</sup> T cells (bulk or Th17-polarized) and CD8<sup>+</sup> T cells redirected with CARs containing CD28, 4-1BB or ICOS-based costimulatory domains. Using multiple mouse tumor models, we demonstrate that the ICOS intracellular domain significantly enhanced the *in vivo* persistence of CAR-expressing CD4<sup>+</sup> T cells, and that both persistence and tumor infiltration were further enhanced by culturing these cells under Th17-polarizing conditions. Importantly, Th17-polarized CD4<sup>+</sup> T cells expressing an ICOS-based CAR significantly increased the circulatory persistence of bulk CD8<sup>+</sup> T cells expressing either CD28- or 4-1BB-based CARs. We further demonstrate that the antitumor effect of CAR-expressing CD8<sup>+</sup> T cells was enhanced when co-injected with ICOS-redirectioned Th17 cells. Collectively, our data suggest that combining Th17 CD4<sup>+</sup> T cells redirectioned with an ICOS-based CAR with CD8<sup>+</sup> CAR-T cells will enhance their persistence and antitumor efficacy.

#### Authors' details

<sup>1</sup>University of Pennsylvania, Philadelphia, PA, USA. <sup>2</sup>University of Pennsylvania, Hatboro, PA, USA. <sup>3</sup>University of Pennsylvania, Poland.

Published: 6 November 2014

<sup>1</sup>University of Pennsylvania, Philadelphia, PA, USA

Full list of author information is available at the end of the article



#### Reference

1. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Lee J, Posey AD, Frigault MJ, Scholler J, Scholler N, Bonneau R, June CH: **ICOS-based chimeric antigen receptors sustain bipolar TH17/TH1 cells.** *ICOS-Based Chimeric Antigen Receptors Program Bipolar TH17/TH1 Cells*, *Blood* 2014, July 1, doi:10.1182/blood-2013-10-535245.

doi:10.1186/2051-1426-2-S3-P244

**Cite this article as:** Guedan et al.: Enhancing T cell persistence of CAR-redirectioned T cells in solid tumors. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P244.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

